|
Age [years]
|
46 (35.6-57.1)
|
49.7 (38.6-64.3)
|
<0.01
| |
|
Gender, female
|
122 (54.2)
|
55 (30.6)
|
<0.0001
|
2.69 (1.78-4.06)
|
|
Referring physician
| | | | |
|
Inpatients
|
108 (48.0)
|
114 (63.3)
|
<0.01
|
0.56 (0.38-0.84)
|
|
Outpatients referred by cardiologists
|
98 (43.6)
|
56 (31.1)
|
<0.05
|
1.71 (1.13-2.58)
|
|
Outpatients referred by general practitioners
|
19 (8.4)
|
10 (5.6)
|
0.26
|
1.57 (0.71-3.46)
|
|
Primary cardiac symptoms leading to CMR
| | | | |
|
Reduced LVEF
|
15 (6.7)
|
67 (37.2)
|
<0.0001
|
0.12 (0.07-0.22)
|
|
Pericardial effusion
|
4 (1.8)
|
2 (1.1)
|
0.58
|
1.61 (0.29-8.90)
|
|
ECG abnormality
|
77 (34.2)
|
54 (30.0)
|
0.37
|
1.21 (0.80-1.85)
|
|
Palpitations
|
66 (29.3)
|
26 (14.4)
|
<0.001
|
2.46 (1.48-4.07)
|
|
Dyspnea
|
59 (26.2)
|
78 (43.3)
|
<0.001
|
0.46 (0.31-0.71)
|
|
Angina/Chest pain
|
132 (58.7)
|
85 (47.2)
|
<0.05
|
1.59 (1.07-2.35)
|
|
Abnormal fatigue
|
57 (25.3)
|
39 (21.8)
|
0.41
|
1.22 (0.77-1.94)
|
|
Wall motion abnormality
|
8 (3.6)
|
9 (5.0)
|
0.47
|
0.70 (0.26-1.85)
|
|
Ventricular arrythmias/Extrasystoles
|
29 (12.9)
|
16 (8.9)
|
0.20
|
1.52 (0.80-2.89)
|
|
Aborted SCD
|
3 (1.3)
|
3 (1.7)
|
0.78
|
0.80 (0.16-4.00)
|
|
Viral prodrome/history of infectious symptoms
|
69 (30.7)
|
61 (33.9)
|
0.49
|
0.86 (0.57-1.31)
|
|
Atrial fibrillation
|
14 (6.2)
|
36 (20.1)
|
<0.0001
|
0.26 (0.14-0.51)
|
|
Elevated troponin
|
8(3.6)
|
30 (16.7)
|
<0.0001
|
0.18 (0.08-0.41)
|
|
EMB performed
|
12 (5.7)
|
66 (38.6)
|
<0.0001
|
0.10 (0.05-0.19)
|
|
Histopathological myocarditis in EMB
|
7 (58.3)
|
46 (70.8)
|
0.39
|
0.58 (0.16-2.05)
|
|
CMR imaging parameters
| | | | |
|
LVEF [%]
|
66 (62.0-70.0)
|
54 (38.0-63.0)
|
<0.0001
| |
|
LV-EDV [ml]
|
122 (103–148)
|
160 (128–204)
|
<0.0001
| |
|
LV-ESV [ml]
|
42 (32.0-51.5)
|
72 (52–109)
|
<0.0001
| |
|
LVEDD [mm]
|
48 (44–52)
|
54 (49–59)
|
<0.0001
| |
|
Pericardial effusion present
|
0
|
76 (42.5)
|
<0.0001
| |
|
LGE present
|
0
|
114 (64.0)
|
<0.0001
| |
|
Symptoms at follow-up
| | | | |
|
Angina pectoris
|
40 (19.8)
|
23 (15.0)
|
0.24
|
1.40 (0.80-2.45)
|
|
Other chest pain (non anginal)
|
17 (8.5)
|
15 (9.8)
|
0.66
|
0.85 (0.41-1.76)
|
|
Palpitations
|
34 (16.9)
|
22 (14.4)
|
0.52
|
1.21 (0.68-2.17)
|
|
NYHA class ≥ 2
|
53 (24.9)
|
58 (36.3)
|
<0.05
|
0.58 (0.37-0.91)
|
|
Medication
| | | | |
|
Betablockers at follow-up
|
51 (24.4)
|
80 (49.1)
|
<0.0001
|
0.33 (0.22-0.52)
|
|
ACEI/ARB at follow-up
|
39 (18.7)
|
68 (41.7)
|
<0.0001
|
0.32 (0.20-0.51)
|
|
Events during follow-up
| | | | |
|
Death
|
2 (0.9)
|
11 (6.1)
|
<0.01
|
0.14 (0.03-0.63)
|
|
Cardiac death
|
0
|
7 (63.6)
|
0.51
| |
|
Aborted SCD
|
0
|
1 (0.6)
|
0.25
| |
|
ICD shocks
|
0
|
2 (1.3)
|
0.10
| |
|
Hospitalization for heart failure
|
1 (0.5)
|
16 (9.5)
|
<0.0001
|
0.04 (0.01-0.34)
|
